Ikena Oncology, Inc.·4

Feb 4, 6:09 PM ET

Tessier Maude 4

4 · Ikena Oncology, Inc. · Filed Feb 4, 2022

Insider Transaction Report

Form 4
Period: 2022-02-02
Tessier Maude
Chief Business Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-02-02+40,00040,000 total
    Exercise: $11.45Exp: 2032-02-02Common Stock (40,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION